The purpose of this study is to evaluate the application value of circulating tumor DNA(ctDNA) with efficacy evaluation and prognostic assessment in patients with unresectable SCLC, who were receiving radiotherapy and chemotherapy treatment.
1. According to each point in time of ctDNA, to analyze the dynamic changes of tumor burden and clonal subtypes which to evaluate the application value of ctDNA in curative efficacy evaluation. 2. Compare the two time points before and after radiotherapy and chemotherapy treatment of the cell free DNA (cfDNA) concentration and tumor burden, analysis the correlation between the changes and prognosis.
Study Type
OBSERVATIONAL
Enrollment
40
observe the association of ctDNA with efficacy of treatment
ctDNA mutation profile at baseline
ctDNA mutation will be detected, PyClone based clonal analysis will be performed to analyze the clonal dominance
Time frame: before treatment ctDNA mutation analysis and clonal analysis (each cycle is 3 weeks)
the evolution of ctDNA mutation profile during treatment
ctDNA mutation will be detected, PyClone based clonal analysis will be performed to analyze the clonal dominance
Time frame: After the first cycle of first line treatment upon physicians' request, ctDNA mutation analysis and clonal analysis (each cycle is 3 weeks)
the evolution of ctDNA mutation profile during treatment
ctDNA mutation will be detected, PyClone based clonal analysis will be performed to analyze the clonal dominance
Time frame: After finished the first line treatment, ctDNA mutation analysis and clonal analysis (each cycle is 3 weeks)
PFS
Progression free of survival
Time frame: From the first line treatment to the time of disease progression (through study completion, an average of 5 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.